Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company's products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA ne… Read more
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) - Total Liabilities
Latest total liabilities as of June 2025: CN¥619.25 Million CNY
Based on the latest financial reports, Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) has total liabilities worth CN¥619.25 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A - Total Liabilities Trend (2019–2024)
This chart illustrates how Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grocery Outlet Holding Corp
NASDAQ:GO
|
USA | $2.11 Billion |
|
Alerus Financial Corp
NASDAQ:ALRS
|
USA | $4.67 Billion |
|
Eastman Kodak Co
NYSE:KODK
|
USA | $1.21 Billion |
|
STAAR Surgical Company
NASDAQ:STAA
|
USA | $102.58 Million |
|
Universal Health Realty Income Trust
NYSE:UHT
|
USA | $409.46 Million |
|
Raffles Medical Group Ltd
F:02M1
|
Germany | €455.26 Million |
|
Xiamen Port Development Co Ltd
SHE:000905
|
China | CN¥6.96 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (2019–2024)
The table below shows the annual total liabilities of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥670.83 Million | -15.88% |
| 2023-12-31 | CN¥797.44 Million | +7.85% |
| 2022-12-31 | CN¥739.41 Million | +5.27% |
| 2021-12-31 | CN¥702.41 Million | +82.59% |
| 2020-12-31 | CN¥384.69 Million | +14.31% |
| 2019-12-31 | CN¥336.54 Million | -- |